Implications of continued response after autologous stem cell transplantation for multiple myeloma

被引：18

作者：

Gonsalves, Wilson I.

Gertz, Morie A.

Dispenzieri, Angela

Lacy, Martha Q.

Lin, Yi

Singh, Preet P.

Gupta, Vinay

Hayman, Suzanne R.

Buadi, Francis K.

Dingli, David

Kapoor, Prashant

McCurdy, Arleigh R.

Kumar, Shaji K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

来源：

BLOOD | 2013年 / 122卷 / 10期

基金：

美国国家卫生研究院;

关键词：

RISK STRATIFICATION; POOR-PROGNOSIS; THERAPY; DEXAMETHASONE; MAINTENANCE; THALIDOMIDE; SURVIVAL; CRITERIA;

D O I：

10.1182/blood-2013-03-492678

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Patients undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM) undergo disease assessment approximately 100 days later. Some patients continue to have a decline in their serum or urine monoclonal protein after day 100 in the absence of additional therapy. We evaluated 430 MM patients who underwent ASCT within 12 months of their diagnosis and had not achieved a complete remission at day 100. Of these patients, 167 (39%) had a continued response after day 100 without additional therapy. When compared with patients who did not (n = 263), those who had a continued response had a longer progression-free survival (35 vs 13 months, P <.001), time to next therapy (43 vs 16 months, P <.001), and overall survival (96 vs 57 months, P <.001). This phenomenon of a continued response maintained prognostic value in a multivariable analysis and should be considered when interpreting posttransplant responses.

引用

页码：1746 / 1749

页数：4

共 21 条

[1]

[Anonymous], 1969, BR J HAEMATOL, P607

[2]

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[3]

A RANDOMIZED TRIAL OF MAINTENANCE VERSUS NO MAINTENANCE MELPHALAN AND PREDNISONE IN RESPONDING MULTIPLE-MYELOMA PATIENTS [J].

BELCH, A ;

SHELLEY, W ;

BERGSAGEL, D ;

WILSON, K ;

KLIMO, P ;

WHITE, D ;

WILLAN, A .

BRITISH JOURNAL OF CANCER, 1988, 57 (01) :94-99

[4]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[5]

EARLY RESPONDER MYELOMA - KINETIC-STUDIES IDENTIFY A PATIENT SUBGROUP CHARACTERIZED BY VERY POOR PROGNOSIS [J].

BOCCADORO, M ;

MARMONT, F ;

TRIBALTO, M ;

FOSSATI, G ;

REDOGLIA, V ;

BATTAGLIO, S ;

MASSAIA, M ;

GALLAMINI, A ;

COMOTTI, B ;

BARBUI, T ;

CAMPOBASSO, N ;

DAMMACCO, F ;

CANTONETTI, M ;

PETRUCCI, MT ;

MANDELLI, F ;

RESEGOTTI, L ;

PILERI, A .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :119-125

[6]

International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[7]

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Greipp, PR ;

Litzow, MR ;

Henderson, KJ ;

Van Wier, SA ;

Ahmann, GJ ;

Fonseca, R .

BLOOD, 2005, 106 (08) :2837-2840

[8]

Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies [J].

Kapoor, Prashant ;

Fonseca, Rafael ;

Rajkumar, S. Vincent ;

Sinha, Shirshendu ;

Gertz, Morie A. ;

Stewart, A. Keith ;

Bergsagel, P. Leif ;

Lacy, Martha Q. ;

Dingli, David D. ;

Ketterling, Rhett P. ;

Buadi, Francis ;

Kyle, Robert A. ;

Witzig, Thomas E. ;

Greipp, Philip R. ;

Dispenzieri, Angela ;

Kumar, Shaji .

MAYO CLINIC PROCEEDINGS, 2010, 85 (06) :532-537

[9]

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics [J].

Kumar, Shaji ;

Fonseca, Rafael ;

Ketterling, Rhett P. ;

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Gertz, Morie A. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Knudson, Ryan A. ;

Greenberg, Alexandra ;

Russell, Stephen J. ;

Zeldenrust, Steven R. ;

Lust, John A. ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Rajkumar, S. Vincent .

BLOOD, 2012, 119 (09) :2100-2105

[10]

Stem cell transplantation for multiple myeloma [J].

Kumar, Shaji .

CURRENT OPINION IN ONCOLOGY, 2009, 21 (02) :162-170

← 1 2 3 →